Clinical trial
Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in…
NCT05296525 · Gamida Cell ltd, Industry · Terminated
Key facts
| NCT number | NCT05296525 |
|---|---|
| Title | Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL |
| Official title | A Phase I/II Multicenter Study Evaluating the Safety and Efficacy of Allogeneic GDA-201 Natural Killer Cells in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma |
| Lead sponsor | Gamida Cell ltd, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin Lymphoma |
| Intervention type | Drug |
| Interventions | GDA-201 |
| Enrollment | 13 |
| Start date | Jul 5, 2022 |
| Primary completion | Apr 22, 2024 |
| Completion | Apr 22, 2024 |
| First posted | Mar 25, 2022 |
| Last update posted | Mar 25, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: